Recipharm, BIAL Extend Opicapone API Supply Agreement
Recipharm and BIAL have expanded their long-term supply agreement for the global manufacture and supply of opicapone API.
Contract development and manufacturing organization, Recipharm, and Portuguese pharma company, BIAL, revealed that they have expanded the long-term supply agreement for the global manufacture and supply of opicapone API.
According to an Oct. 1, 2020 press release, the expansion of the agreement follows the successful marketing authorization application for BIAL’s Ongentys product—an adjunctive therapy used to treat patients with Parkinson’s disease—in Japan. The opicapone API, which is manufactured at Recipharm’s Cramlington facility in the United Kingdom, is used to formulate the drug product.
“We have worked for several years with process development and scale up to commercial scale of the manufacturing of opicapone,” said Bernard Pluta, president, Development Services at Recipharm, in the press release. “The approval in Japan marks a significant milestone for this important product for patients suffering Parkinson’s disease and we look forward to continue to work together with BIAL to supply opicapone to Japan and elsewhere.”
Source: Recipharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
